Details for Patent: 7,802,568

Summary for Patent: 7,802,568

Title:	Cartridge for a liquid
Abstract:	For meteredly dispensing a liquid over a period of several months from a container which can be stored over a long period of time, the need is for a container which is practically diffusion-tight and in which the liquid does not come into contact with the ambient atmosphere. The cartridge according to the invention is a three-shell container comprising a collapsible bag which contains the liquid, a container which is stable in respect of shape and a stiff metal casing. The cartridge can be releasably connected to a dispensing device. The cartridge can be provided with a micro-opening with which the time for pressure equalisation between the cartridge and the ambient atmosphere can be adjusted. The cartridge is suitable for aqueous and for alcoholic liquids which contain a pharmaceutically active substance. The liquid in the cartridge is protected from external influences. The cartridge can be used in an atomiser for producing an inhalable aerosol for the treatment of illnesses.
Inventor(s):	Eicher; Joachim (Dortmund, DE), Geser; Johannes (Dortmund, DE), Hausmann; Matthias (Dortmund, DE), Schyra; Michael (Wuppertal, DE), Wuttke; Gilbert (Dortmund, DE), Fiol; Andreas (Wuppertal, DE), Kladders; Heinrich (Muelheim, DE), Hochrainer; Dieter (Bingen am Rhein, DE), Zierenberg; Bernd (Bingen am Rhein, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	11/232,896
Patent Claim Types: see list of patent claims	Device;
Scope and claims summary:	Patent Analysis: United States Patent 7802568 Issued in 2010, United States Patent 7802568 revolves around the area of recombinant vectors based on the measles virus. This patent, which has since expired, primarily focuses on recombinant measles vectors intended to deliver therapeutic or prophylactic genes into mammalian cells. Key claims within the patent describe improved methods for the production and application of these vectors. Manner of Construction and Scope The instant patent provides its applicants with extensive claims on vectors engineered within the viral envelope of the measles virus. The patent addresses improved methods focusing on virus attenuation, enabling safer vector gene transfers, further processing from recombinant RNA within mammalian cells and more. Notably, the inventors explore specific serotypes (respiratory, dental, ocular, oral and pathogenic etc.) while enhancing the potential within measles vector-based gene therapy techniques. Key Claims and Impact The patent applies various nucleic acid constructs integrated with measles virus components allowing the overall formulation system to become much more efficient and cost-effective. These recombinant vectors assist by inserting and replicating within host cells making them highly competent for vaccine and therapeutics treatment. This patent comprises critical inventions that primarily address measles vectors attenuation ensuring host safety. Those methods detail various inactivating substances allowing inactivated measles vaccine delivery within desired locations in vector gene expression with some preferred claims demonstrating intracellular gene transfer applications related measles vaccine vectors. Adequate Application and Discussion of Claims Claims provided within the patent give its inventors exclusive rights over some recombinant constructs and related treatment applications. The application and scope of patent protection typically pertain to an invention disclosed providing superior recombinant vectors for enhanced genetic expressions from various methods. Though the patent's claims have expired, this work contributes crucial technology development in the field of gene therapy, specifically facilitating promising therapeutic and prophylactic applications. These inventive applications outline measles virus vector-based therapy exploration. Implication in Future Research and Discovery Looking forward in scientific and healthcare developments, modern breakthroughs largely rely on complex discoveries rooted from similar breakthrough discoveries expressed and detailed within existing patent applications. As we accelerate in this trajectory, inventive applications in recombinant proteins engineering continue the fast pace on our paths, significantly influencing life-saving medication discoveries pushing life-sciences' ground. While this specific patent has now expired, the comprehensive discoveries established in that patent greatly impact the continued refinement of recombinant vaccine technologies - further impacting disease modelling for therapy practice and discovery in gene therapy.

Drugs Protected by US Patent 7,802,568

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 7,802,568

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	199 40 713	Feb 23, 1999
Malaysia	PI 99 00627	Aug 26, 1999

International Family Members for US Patent 7,802,568

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	022717
Austria	277582
Australia	3422600
Australia	759881
Bulgaria	105785
Bulgaria	64454
Brazil	0008423